Grifols, S.A. (BME:GRF)
8.83
-0.12 (-1.36%)
Apr 28, 2026, 1:35 PM CET
Grifols Revenue
In the year 2025, Grifols had annual revenue of 7.52B EUR with 4.33% growth. Grifols had revenue of 1.98B in the quarter ending December 31, 2025, with 0.32% growth.
Revenue
7.52B
Revenue Growth
+4.33%
P/S Ratio
0.74
Revenue / Employee
297.89K
Employees
25,258
Market Cap
5.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.52B | 312.00M | 4.33% |
| Dec 31, 2024 | 7.21B | 620.00M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.03M | 8.71% |
| Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Almirall | 1.11B |
| Laboratorios Farmaceuticos Rovi | 743.48M |
| Faes Farma | 626.99M |
| Laboratorio Reig Jofre | 336.68M |
| Clínica Baviera | 304.91M |
| Prim, S.A. | 251.89M |
| Pharma Mar | 221.39M |
| Atrys Health | 144.31M |
Grifols News
- 19 days ago - Manitoba medical examiner says investigations complete in deaths of plasma donors - CBC News
- 25 days ago - Grifols (GRFS) Faces Health Canada's New Regulations After Inspection Failures - GuruFocus
- 26 days ago - Health Canada slaps new conditions on plasma donation company Grifols, still reviewing 2 Manitoba deaths - CBC News
- 4 weeks ago - Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates - GlobeNewsWire
- 4 weeks ago - Bullish Two Hundred Day Moving Average Cross - GRF - Nasdaq
- 4 weeks ago - Grifols approves IPO of its US biopharma business - Reuters
- 5 weeks ago - Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease - GlobeNewsWire
- 6 weeks ago - Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance - GlobeNewsWire